IGDRP Roadmap to 2020

  • by IGDRP - 21 December 2016 - 12:07pm

 The availability of quality generic medicines plays an increasingly important role in helping to address rising health care costs and in promoting access to essential medicines worldwide. This, however, has led to significant pressures on regulatory authorities (RAs) tasked with the review and authorisation of these drug products. Among other objectives, the IGDRP initiative has the ambition to increase the efficiency of review procedures and reduce regulatory burden without comprising the safety, efficacy, and quality of generic medicines. Given these challenges, the benefits of regulatory cooperation, convergence and harmonisation have long been recognised.

The IGDRP Steering Committee is pleased to announce the release of the IGDRP Roadmap to 2020 describing these shared goals and objectives. Health Canada led the development of the Roadmap which makes available a strategic vision to articulate and guide the collective efforts of IGDRP in terms of where we are going and how we are going to get there. The document describes the five overarching strategic priorities for the initiative as well the key objectives for each of these priorities.

The IGDRP will develop and maintain strong, formal communication channels with other international initiatives and is currently developing performance measurement tools to assess the impact and success of the programme against its intended objectives.